Abstract 7087: Sample-sparing immunoassays for early detection of cancer

Abstract Research Use Only (RUO) sample-sparing MULTI-ARRAY immunoassays have been developed for several well-established cancer markers. The primary focus of this project is the development of assays to support research of suspicious lung nodules, but many of these selected markers are also relevant to other cancer types. These immunoassays include a serology panel, two biomarker panels, and a single-marker assay. The serology panel includes assays to detect autoantibodies to p53, CTAG-1, and CTAG-2. This panel requires 25 μL of 2, 500-fold diluted serum or plasma. A biomarker panel requiring 25 μL of 100-fold diluted serum or plasma detects the following biomarkers: CA15-3, SCFR/Kit, ErbB2, IGFBP-2, MIF, MMP-2, MMP-9 (total), REG4, S100A6, and TNF-RI. A second biomarker panel requiring 25 μLof 10-fold diluted serum or plasma detects the following biomarkers: CA125, Ca19-9, CEACAM-5 (CEA), EGFR, VEGFR-1/Flt-1, FLT3L, HE4, MMP-3 (total), and osteopontin. Finally, an assay for the core lung cancer biomarker cytokeratin-19 was developed. All assays had dynamic ranges that span 3-4 logs and are sufficiently sensitive to measure native levels in commercially sourced samples from apparently healthy individuals. The assays were preliminarily evaluated using more than 100 commercially sourced serum or plasma samples from apparently healthy individuals and more than 100 commercially sourced serum or plasma samples from patients with lung or other cancers. Many of the biomarkers had significantly different concentrations in several cancers compared to samples from apparently healthy individuals. These RUO assays may be useful in identifying biomarkers for a multi-marker panel to study early cancer. Citation Format: Mingyue Wang, Jermaine Brown, Daniel Lee, Salvia Misaghian, Taron Gorham, Leonid Dzantiev, Anu Mathew, Martin Stengelin, Ji Qiu, Karen Anderson, Joshua LaBaer, George Sigal, Jacob Wohlstadter. Sample-sparing immunoassays for early detection of cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7087.